Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

12.93 -3.07

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.87

Max

13.34

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-4.3M -18M
Pelnas, tenkantis vienai akcijai	-0.19
Darbuotojai	37
EBITDA	-5.3M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+121.31% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	86M 1.2B
Ankstesnė atidarymo kaina	16
Ankstesnė uždarymo kaina	12.93

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-09 23:56; UTC

Revolve Group Inc shares are higher in after-market hours, maintaining an upward trend since Wednesday's close, despite being below the 20-day moving average.

2026-09-09 23:56; UTC

Correlated Moves

Procore Technologies Inc shares are higher in after-market hours, recovering from an initial decline. The stock remains below its 20-day moving average.

2026-09-09 23:56; UTC

BlackLine Inc. shares rose in after-market trading, recovering from an initial dip. The stock remains below its 20-day moving average amid broader market challenges.

2026-09-09 23:56; UTC

MetLife Inc shares are lower in after-market hours amid heightened market anxiety over geopolitical tensions and upcoming economic data releases.

2026-09-09 23:56; UTC

Warner Bros Discovery Inc. shares are higher in after-market trading, despite earlier fluctuations and amid broader market anxiety over geopolitical tensions and economic data.

2026-09-09 23:56; UTC

JinkoSolar Holding Co Ltd shares are lower in after-market hours, continuing a decline amid market anxiety over geopolitical tensions and upcoming economic data releases.

2026-09-09 23:56; UTC

No specific news was identified for Solaredge Technologies. Shares traded roughly flat in after-market hours, remaining near the upper end of their one-month range.

2026-09-09 23:53; UTC

Gossamer Bio Inc. shares are lower in after-market hours following a significant decline since Wednesday's close, despite an earlier attempt to recover.

2026-09-09 23:52; UTC

ACI Worldwide shares declined in after-market trading, continuing a downward trend from regular trading and reflecting ongoing selling pressure amid broader market conditions.

2026-09-09 23:52; UTC

The NZD/CHF is trading lower during Wednesday's session, reflecting routine movement near its one-month trading range's lower end. No specific news was identified.

2026-09-09 23:51; UTC

Correlated Moves

Ares Management shares are higher in after-market trading, reflecting positive market conditions and aligning with upward trends in correlated assets like Brookfield Corp.

2026-09-09 23:51; UTC

Correlated Moves

ACNB Corp shares are lower in after-market hours, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

2026-09-09 23:51; UTC

News

Toll Brothers Inc. shares are lower in after-market trading, continuing a trend of declining performance amid broader market pressures and rising crude oil prices.

2026-09-09 23:51; UTC

Lamb Weston Holdings Inc shares are higher in after-market hours, reflecting an increase since Wednesday's close, despite recent underperformance and no specific news identified.

2026-09-09 23:51; UTC

ManpowerGroup Inc. shares are lower in after-market hours, continuing a decline below the 20-day moving average amid broader market weakness.

2026-09-09 23:51; UTC

MVB Financial Corp shares traded higher in after-market hours, reaching 0.42% above Wednesday's close and remaining above their 20-day moving average.

2026-09-09 23:51; UTC

Travelers Companies Inc shares are higher in after-market hours, reaching a peak return after an initial dip. No specific news was identified for this movement.

2026-09-09 23:51; UTC

Movado Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

2026-09-09 23:51; UTC

UK Housing Market Shows Signs of Stabilization with Slight Improvement in House Price Balance, Amidst Cautious Optimism and Ongoing Economic Challenges

2026-09-09 23:51; UTC

Existing Home Sales Expected to Decline Amid High Mortgage Rates and Decreased Buyer Demand

2026-09-09 23:51; UTC

US Existing Home Sales Data for August 2026 Expected at 3.98 Million Amid Rising Inventory and High Mortgage Rates.

2026-09-09 23:51; UTC

Brazil's Central Bank Faces Critical Interest Rate Decision Amid Inflation Concerns and Economic Resilience on September 16, 2026.

2026-09-09 23:51; UTC

Chubb Limited shares are lower in after-market hours, continuing a trend of declining prices. The stock is below its 20-day moving average.

2026-09-09 23:51; UTC

Amerisafe Inc shares are higher after market hours, despite a slight decline earlier. The stock remains below its 20-day moving average.

2026-09-09 23:51; UTC

Correlated Moves

Carlyle Group Inc is trading higher in after-market hours, rebounding from three consecutive lower sessions amid broader positive market dynamics despite rising crude oil prices.

2026-09-09 23:51; UTC

Patrick Industries Inc. shares declined after market hours, continuing a trend of lower closes. The stock remains significantly below the 20-day moving average.

2026-09-09 23:51; UTC

News

Lakeland Industries reported a fiscal Q2 net loss of $4.9 million and lower-than-expected sales, leading shares to decline in after-market trading.

2026-09-09 23:51; UTC

News

Limoneira Co reported third-quarter results that missed expectations, with revenues falling to $43.8 million and shares trading lower in after-market hours.

2026-09-09 23:51; UTC

Correlated Moves

EUR/CHF is trading higher, recovering from earlier lows and reflecting unusual intraday activity near the upper end of its one-month range.

2026-09-09 23:51; UTC

GBP/CHF is trading higher during Wednesday's session, recovering from an early dip and settling near the upper end of its one-month trading range.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

121.31% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD 121.31%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.